CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
pemetrexeddrug
Likely dose
Pemetrexed 500 mg/m² intravenously every 21 days for 3 cycles, with folic acidAI-extracted
Key inclusion· 5
  • ✓Histologically or cytologically confirmed adenocarcinoma of the rectum, resectable/operable
  • ✓No prior therapy for rectal cancer
  • ✓ECOG performance status 0 or 1
  • ✓Adequate organ function
Key exclusion· 7
  • ✕Concurrent anti-tumor therapy
  • ✕Serious concomitant systemic disorders
  • ✕Second primary malignancy
  • ✕History of significant neurological or mental disorder, including seizures or dementia

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00330915
NCT00330915Phase 2Completed
CompareCT.gov

A Feasibility Study of Pemetrexed Single Agent and Folic Acid Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Eli Lilly and Company·interventional·Posted May 29, 2006·Updated Jul 21, 2009

In Brief

A Phase 2 clinical trial evaluating pemetrexed for Rectal Neoplasms. Completed, enrolled 37 participants across 1 site.

Detailed Summary

The purpose of this study is to help answer the following research questions: If the study drug Pemetrexed can help patients with rectal cancer; If molecular biological parameters are correlated respectively changing due to cytotoxic treatment with Pemetrexed; To evaluate adverse events

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRectal Neoplasms
CountriesSweden
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 29, 2006
Enrollment StartJun 1, 2006
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 20.1 years ago

Interventions

pemetrexeddrug

500 mg/m2, intravenous (IV), every 21 days x 3 cycles